```html

Zollinger‑Ellison Associated Diabetes

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum, causing excessive gastric acid secretion. When the chronic hyperacidity damages the pancreas or interferes with insulin secretion, patients can develop a secondary form of diabetes mellitus—often called “Zollinger‑Ellison associated diabetes.”

Who it affects: ZES occurs most commonly in adults ages 30‑60, with a slight male predominance (≈55%). Approximately 10‑20 % of patients with ZES develop diabetes, making the combined condition exceptionally uncommon (1).

Prevalence: Isolated gastrinomas have an incidence of 0.5–2 per million per year. Because only a minority of these patients develop diabetes, the overall prevalence of Zollinger‑Ellison associated diabetes is estimated at < 0.1 cases per million people worldwide (2).

Symptoms

Symptoms stem from two sources: the acid‑hypersecreting tumor and the resulting diabetes. Both sets can overlap, so it is important to recognize each component.

Symptoms related to Zollinger‑Ellison syndrome

• Peptic ulcer disease (PUD): recurrent or multiple ulcers in the duodenum or jejunum.
• Abdominal pain: burning or gnawing pain that may improve with meals.
• Diarrhea or steatorrhea: excess acid inactivates pancreatic enzymes, leading to fat malabsorption.
• Vomiting: can be due to ulcer complications or acid reflux.
• Weight loss: from malabsorption and chronic disease.
• Upper GI bleeding: melena or hematemesis from ulcer erosion.

Symptoms related to diabetes mellitus

• Polyuria: frequent urination.
• Polydipsia: excessive thirst.
• Polyphagia: increased hunger.
• Unexplained weight loss: despite increased appetite.
• Fatigue: due to impaired glucose utilization.
• Blurred vision, slow wound healing, recurrent infections: classic hyperglycemia signs.

Combined presentation

Patients may notice that their diabetes appears after years of chronic ulcer disease, or that glucose control worsens during acute acid‑related crises. Recognizing this pattern helps clinicians differentiate secondary diabetes from type 1 or type 2.

Causes and Risk Factors

The underlying driver is the gastrinoma itself, but several mechanisms link it to diabetes.

Pathophysiology

1. Acid‑mediated pancreatic injury: Gastric acid refluxes into the duodenum, deactivates pancreatic enzymes and damages pancreatic acinar cells, leading to chronic pancreatitis and impaired β‑cell function.
2. Islet‑cell hormone imbalance: Gastrin may have direct trophic effects on islet cells, altering insulin secretion.
3. Malabsorption‑induced nutrient deficiencies: Deficiencies of magnesium, zinc and fat‑soluble vitamins can impair insulin synthesis.
4. Medication effect: Long‑term use of high‑dose proton pump inhibitors (PPIs) can mask hypoglycemia and affect glucose metabolism.

Who is at higher risk?

• Patients with sporadic gastrinomas: 10‑20 % develop diabetes.
• Individuals with Multiple Endocrine Neoplasia type 1 (MEN‑1): up to 30 % of MEN‑1‑related gastrinomas develop pancreatic exocrine insufficiency and diabetes (3).
• Long‑standing untreated acid hypersecretion: >5 years of uncontrolled ulcers increases pancreatic damage risk.
• Family history of pancreatic endocrine disorders.
• Age >40 years and obesity: these conventional risk factors for type 2 diabetes add to the secondary risk.

Diagnosis

Because the two conditions are interrelated, a systematic approach is essential.

Evaluating Zollinger‑Ellison syndrome

• Fasting serum gastrin level: >1000 pg/mL (10‑fold elevation) strongly suggests gastrinoma, especially when gastric pH <2.
• Secretin stimulation test: an increase in gastrin >200 pg/mL after IV secretin is diagnostic.
• Imaging:
  • Contrast‑enhanced CT or MRI of the abdomen to locate the tumor.
  • Endoscopic ultrasound (EUS) – highly sensitive for small duodenal lesions.
  • Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT for metastatic disease.
• Upper endoscopy: to document ulcer burden and obtain biopsies if needed.

Evaluating diabetes

• Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L) on two occasions, or
• HbA1c ≥6.5 % (48 mmol/mol), or
• 2‑hour oral glucose tolerance test ≥200 mg/dL (11.1 mmol/L).

When diabetes is diagnosed in a patient already known to have ZES, clinicians should assess pancreatic exocrine function (fecal elastase, fecal fat) and review medication history.

Differential diagnosis

Other causes of secondary diabetes (chronic pancreatitis, cystic fibrosis, hemochromatosis) must be ruled out, as must type 1 (autoantibody testing) and type 2 diabetes.

Treatment Options

Management targets both acid hypersecretion and glucose control, while preserving pancreatic function.

Control of gastric acid

• High‑dose proton pump inhibitors (PPIs): Omeprazole 40‑80 mg daily or equivalent; they achieve >90 % symptom control (4).
• Histamine‑2 receptor antagonists (H2 blockers): can be added for breakthrough symptoms.
• Somatostatin analogs (Octreotide, Lanreotide): suppress gastrin release and may shrink tumors; useful especially in MEN‑1 or metastatic disease.

Surgical management

Curative resection of localized gastrinomas (duodenotomy, pancreatic enucleation, or Whipple procedure) offers the best chance of long‑term remission. Approximately 60‑70 % of sporadic gastrinomas are resectable at diagnosis (5).

Diabetes therapy

1. Lifestyle modification: balanced low‑glycemic diet, regular aerobic activity (150 min/week), weight management.
2. Metformin: first‑line unless contraindicated; may improve insulin sensitivity and has a favorable cardiovascular profile.
3. Insulin: required in >30 % of patients when β‑cell loss is significant. Basal‑bolus regimens or insulin pumps provide flexibility.
4. GLP‑1 receptor agonists or DPP‑4 inhibitors: can be used if there is residual β‑cell function; watch for possible nausea in the setting of ulcer disease.
5. Pancreatic enzyme replacement therapy (PERT): improves nutrient absorption, reduces post‑prandial hyperglycemia caused by malabsorption.

Therapy must be individualized; frequent glucose monitoring (CGM if possible) helps avoid hypoglycemia when acid‑suppression therapy is intensified.

Management of exocrine insufficiency

PERT (e.g., pancrelipase 25,000–40,000 Lipase units per meal) should be started when fecal elastase <200 µg/g, fatty stools, or weight loss are present.

Follow‑up and surveillance

• Every 6–12 months: serum gastrin, gastrin‑stimulating test if symptoms change.
• Annual imaging (CT/MRI) for tumor recurrence.
• HbA1c every 3 months, with more frequent checks after therapy adjustments.

Living with Zollinger‑Ellison Associated Diabetes

Patients often need to juggle two chronic conditions. Below are practical tips.

Daily Management

• Medication schedule: Take PPIs 30 minutes before breakfast and dinner; set alarms for insulin or oral hypoglycemics.
• Meal planning: Small, frequent meals that combine protein, complex carbs, and healthy fats reduce acid spikes and stabilize glucose.
• Hydration: Adequate fluid intake helps prevent kidney stones (a complication of hyperacidity) and supports glucose regulation.
• Monitor blood glucose: Use a glucometer or continuous glucose monitor (CGM); record trends, especially after heavy meals or PPI dose changes.
• Watch for steatorrhea: If stools become pale, bulky, or foul‑smelling, increase PERT dose and contact your provider.
• Physical activity: Aim for moderate‑intensity aerobic exercise (brisk walk, cycling) and resistance training 2–3 times per week; both improve insulin sensitivity and aid weight control.
• Stress management: Stress can exacerbate ulcer pain and raise glucose. Techniques such as deep breathing, yoga, or counseling are beneficial.

Key Lifestyle Adjustments

1. Quit smoking – it worsens ulcer disease and insulin resistance.
2. Limit alcohol – excess alcohol can irritate the gastric mucosa and damage the pancreas.
3. Avoid NSAIDs and aspirin unless prescribed with a protective agent, as they increase ulcer risk.
4. Maintain a healthy body weight (BMI 18.5‑24.9) to lessen insulin demand.

Support Resources

Consider joining patient groups such as the Zollinger‑Ellison Syndrome Foundation or diabetes associations (e.g., ADA). Peer support can provide practical coping strategies and emotional encouragement.

Prevention

Because the syndrome originates from a tumor, primary prevention is limited, but secondary prevention can reduce the likelihood of developing diabetes.

• Early detection of gastrinoma: In patients with refractory ulcers, obtain fasting gastrin levels promptly.
• Prompt acid control: Initiate high‑dose PPIs as soon as ZES is suspected to protect pancreatic tissue.
• Regular screening for pancreatic exocrine insufficiency: Annual fecal elastase testing in known ZES patients.
• Healthy lifestyle: Adequate nutrition, physical activity, and avoidance of pancreatotoxic substances lower the additive risk of type 2 diabetes.

Complications

If left inadequately treated, both components can lead to serious health problems.

Complications of Zollinger‑Ellison syndrome

• Recurrent or perforated peptic ulcers.
• Gastrointestinal bleeding requiring transfusion or endoscopic therapy.
• Chronic pancreatitis and pancreatic duct strictures.
• Metastatic gastrinoma (liver, lymph nodes) in 30‑40 % of sporadic cases.
• Kidney stones from hypercalciuria associated with high gastric acid.

Complications of associated diabetes

• Microvascular disease: retinopathy, nephropathy, peripheral neuropathy.
• Macrovascular disease: accelerated coronary artery disease, stroke.
• Infections – especially skin and urinary tract infections.
• Hypoglycemia risk heightened by erratic gastric emptying or PPI interactions.
• Impaired wound healing, which can be disastrous after ulcer surgery.

Combined impact

The coexistence of chronic ulcer disease, malabsorption, and hyperglycemia creates a vicious cycle that worsens nutritional status, increases hospitalization rates, and raises overall mortality to ≈15 % at 5 years for patients with unresected metastatic gastrinoma plus diabetes (6).

When to Seek Emergency Care

References

1. J. L. Brander et al., “Epidemiology of Gastrinomas and Zollinger‑Ellison Syndrome,” World J Gastroenterol, 2022.
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), “Zollinger‑Ellison Syndrome,” 2023.
3. J. D. Thompson et al., “MEN‑1 associated gastrinomas and pancreatic endocrine dysfunction,” Cleveland Clinic Journal of Medicine, 2021.
4. Mayo Clinic, “Zollinger‑Ellison syndrome treatment,” accessed June 2024.
5. American College of Surgeons, “Management of Gastrinomas,” 2023 guideline.
6. American Diabetes Association, “Standards of Care in Diabetes—2024,” Diabetes Care, 2024.

```